Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.16 Insider Own15.11% Shs Outstand53.80M Perf Week4.73%
Market Cap51.76M Forward P/E- EPS next Y-1.23 Insider Trans-0.79% Shs Float46.25M Perf Month67.96%
Income-116.52M PEG- EPS next Q-0.41 Inst Own46.99% Short Float4.83% Perf Quarter-0.89%
Sales21.23M P/S2.44 EPS this Y-26.16% Inst Trans-0.34% Short Ratio2.45 Perf Half Y-65.20%
Book/sh1.57 P/B0.60 EPS next Y38.58% ROA-70.86% Short Interest2.23M Perf Year-90.56%
Cash/sh1.45 P/C0.66 EPS next 5Y- ROE-86.16% 52W Range0.50 - 10.39 Perf YTD27.86%
Dividend Est.- P/FCF- EPS past 5Y3.05% ROI-126.02% 52W High-90.86% Beta0.70
Dividend TTM- Quick Ratio4.25 Sales past 5Y156.45% Gross Margin62.62% 52W Low90.00% ATR (14)0.11
Dividend Ex-Date- Current Ratio4.40 EPS Y/Y TTM-29.97% Oper. Margin-566.29% RSI (14)65.90 Volatility18.66% 13.74%
Employees106 Debt/Eq0.09 Sales Y/Y TTM-46.17% Profit Margin-548.95% Recom1.40 Target Price5.10
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q-19.82% Payout- Rel Volume1.10 Prev Close0.85
Sales Surprise-50.76% EPS Surprise0.00% Sales Q/Q-55.00% EarningsMar 04 AMC Avg Volume912.31K Price0.95
SMA2042.59% SMA5049.04% SMA200-49.39% Trades Volume1,006,116 Change11.74%
Date Action Analyst Rating Change Price Target Change
Mar-08-23Downgrade BofA Securities Neutral → Underperform $13 → $6
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Feb-12-24 04:01PM
Jan-22-24 10:19AM
Dec-18-23 07:00AM
Nov-14-23 11:04AM
08:48AM Loading…
Nov-13-23 06:00PM
Nov-09-23 11:38AM
Nov-06-23 10:00AM
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
Sep-05-23 07:00AM
02:53AM Loading…
Aug-10-23 02:53AM
Aug-08-23 05:54AM
Aug-07-23 05:15PM
Aug-03-23 07:00AM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
02:00AM Loading…
May-16-23 11:02AM
May-15-23 05:15PM
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
Mar-06-23 07:39PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
Jul-22-22 06:39AM
Jun-30-22 10:19AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
May-09-22 05:25PM
May-04-22 09:05AM
May-03-22 04:01PM
Apr-29-22 07:00AM
Apr-28-22 01:00AM
Apr-13-22 11:17AM
Apr-05-22 07:00AM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner ChristopherPRESIDENT AND CEOFeb 08Sale0.5335,57518,855186,355Feb 12 05:10 PM
Posner ChristopherPRESIDENT AND CEOFeb 01Sale0.554,9812,740221,930Feb 05 04:26 PM
Posner ChristopherPresident and CEONov 02Sale1.223,7964,631164,411Nov 03 04:37 PM
Posner ChristopherPresident and CEOAug 03Sale3.074,30713,222168,207Aug 04 05:21 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJun 23Sale3.512,99310,505153,747Jun 27 04:08 PM
Goncalves JoanaChief Medical OfficerJun 23Sale3.512,7239,55853,681Jun 27 04:07 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Jun 23Sale3.512,4838,71588,563Jun 27 04:09 PM
Posner ChristopherPresident and CEOMay 05Sale4.403,86917,024172,514May 09 04:22 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 04Sale4.912,73313,419156,740Apr 06 05:12 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 04Sale4.912,48112,18291,046Apr 06 05:14 PM
Goncalves JoanaChief Medical OfficerApr 04Sale4.912,48112,18256,404Apr 06 05:13 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 03Sale9.716,80266,047159,473Mar 07 04:46 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 03Sale9.716,25660,74693,527Mar 07 04:44 PM
Goncalves JoanaChief Medical OfficerMar 03Sale9.716,22160,40658,885Mar 07 04:43 PM
Posner ChristopherPresident and CEOMar 03Sale9.715,98758,134176,383Mar 07 04:47 PM